92 related articles for article (PubMed ID: 24910836)
1. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study.
Philip E; Sundaram ML; Das R; Chauhan SK; Deshpande S; Ambhore S; Rathod R; Manjrekar P
Indian J Endocrinol Metab; 2013 Dec; 17(Suppl 3):S674-9. PubMed ID: 24910836
[TBL] [Abstract][Full Text] [Related]
2. Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis.
Kalra S; Sahay RK; Schnell O; Sheu WH; Grzeszczak W; Watada H; Soegondo S; Yamamoto N; Weng J; Rathod R
Indian J Endocrinol Metab; 2013 Oct; 17(Suppl 1):S307-9. PubMed ID: 24251196
[TBL] [Abstract][Full Text] [Related]
3. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study.
Zhang W; Kim D; Philip E; Miyan Z; Barykina I; Schmidt B; Stein H;
Clin Drug Investig; 2013 Apr; 33(4):263-74. PubMed ID: 23435929
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study.
Saboo B; Reddy GC; Juneja S; Kedia AK; Manjrekar P; Rathod R;
Indian J Endocrinol Metab; 2015; 19(1):129-35. PubMed ID: 25593840
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
Pan CY; Landen H
Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
[TBL] [Abstract][Full Text] [Related]
6. An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco.
Shihabi AR; Moussa EM; Sobierajska H; Schmidt B
Diabetes Metab Syndr Obes; 2013; 6():141-50. PubMed ID: 23630429
[TBL] [Abstract][Full Text] [Related]
7. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
Li C; Hung YJ; Qamruddin K; Aziz MF; Stein H; Schmidt B
Diabetes Res Clin Pract; 2011 Apr; 92(1):57-64. PubMed ID: 21251726
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study.
Balaji V
Indian J Endocrinol Metab; 2013 Jul; 17(4):709-15. PubMed ID: 23961491
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
[TBL] [Abstract][Full Text] [Related]
10. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2).
Ghosh S; Tiwaskar M; Chawla R; Jaggi S; Asirvatham A; Panikar V
Diabetes Ther; 2020 Oct; 11(10):2257-2268. PubMed ID: 32779100
[TBL] [Abstract][Full Text] [Related]
11. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
13. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
14. Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose.
Chen PH; Tsai YT; Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Sheu WH; Lin SY
Diabetol Metab Syndr; 2014; 6():68. PubMed ID: 24932223
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
16. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study).
Ghosh S; Trivedi S; Sanyal D; Modi KD; Kharb S
Diabetes Metab Syndr Obes; 2016; 9():347-353. PubMed ID: 27877058
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy.
Kumar A; Prakash AS
J ASEAN Fed Endocr Soc; 2019; 34(1):87-91. PubMed ID: 33442141
[TBL] [Abstract][Full Text] [Related]
18. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Pan CY; Gao Y; Li GW; Zhu XX; Gao X; Liu X
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):304-7. PubMed ID: 19576120
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
20. Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region.
Kalra S; Sahay RK; Schnell O; Sheu WH; Grzeszczak W; Watada H; Soegondo S; Yamamoto N; Weng J; Rathod R
Indian J Endocrinol Metab; 2013 Oct; 17(Suppl 1):S304-6. PubMed ID: 24251195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
